Stephen Chaplin

643 total citations
27 papers, 470 citations indexed

About

Stephen Chaplin is a scholar working on Economics and Econometrics, Epidemiology and General Agricultural and Biological Sciences. According to data from OpenAlex, Stephen Chaplin has authored 27 papers receiving a total of 470 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Economics and Econometrics, 4 papers in Epidemiology and 4 papers in General Agricultural and Biological Sciences. Recurrent topics in Stephen Chaplin's work include Health Systems, Economic Evaluations, Quality of Life (5 papers), Economic and Environmental Valuation (3 papers) and Lipoproteins and Cardiovascular Health (3 papers). Stephen Chaplin is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (5 papers), Economic and Environmental Valuation (3 papers) and Lipoproteins and Cardiovascular Health (3 papers). Stephen Chaplin collaborates with scholars based in United Kingdom, United States and Australia. Stephen Chaplin's co-authors include R E Ferner, Jane Mills, Paul Scuffham, Peter Gaskell, J. Isselstein, Julie Ingram, S. Peel, Hannah Chiswell, John Young and Eileen Burns and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Stephen Chaplin

26 papers receiving 448 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephen Chaplin United Kingdom 14 97 91 74 56 54 27 470
Beatriz Rodríguez-Sánchez Spain 14 97 1.0× 34 0.4× 26 0.4× 101 1.8× 9 0.2× 37 537
Kristina H. Lewis United States 15 71 0.7× 150 1.6× 19 0.3× 49 0.9× 53 1.0× 55 802
Laurence Bérard France 17 28 0.3× 35 0.4× 50 0.7× 12 0.2× 17 0.3× 49 1.1k
Sidy Mohamed Seck Senegal 13 16 0.2× 16 0.2× 22 0.3× 24 0.4× 7 0.1× 57 376
Luke E. Barry Ireland 10 137 1.4× 54 0.6× 6 0.1× 78 1.4× 23 0.4× 23 379
Ritu Rana India 11 16 0.2× 19 0.2× 6 0.1× 39 0.7× 42 0.8× 57 422
Georgina Mulcahy Australia 8 54 0.6× 14 0.2× 10 0.1× 80 1.4× 5 0.1× 9 340
Praween Agrawal India 13 40 0.4× 28 0.3× 4 0.1× 90 1.6× 2 0.0× 32 496
Xiaoguang Yang China 16 18 0.2× 31 0.3× 9 0.1× 19 0.3× 2 0.0× 47 678
Vikki O’Neill United Kingdom 8 116 1.2× 11 0.1× 2 0.0× 34 0.6× 27 0.5× 13 294

Countries citing papers authored by Stephen Chaplin

Since Specialization
Citations

This map shows the geographic impact of Stephen Chaplin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Chaplin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Chaplin more than expected).

Fields of papers citing papers by Stephen Chaplin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Chaplin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Chaplin. The network helps show where Stephen Chaplin may publish in the future.

Co-authorship network of co-authors of Stephen Chaplin

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Chaplin. A scholar is included among the top collaborators of Stephen Chaplin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Chaplin. Stephen Chaplin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chaplin, Stephen, et al.. (2024). Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective. Journal of Managed Care & Specialty Pharmacy. 30(11). 1226–1238. 1 indexed citations
3.
Aapro, Matti, Stephen Chaplin, Paul Cornes, et al.. (2023). Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer. Supportive Care in Cancer. 31(10). 581–581. 4 indexed citations
4.
Li, Edward C., et al.. (2021). Trends in pegfilgrastim average sales price and cost-effectiveness of primary prophylaxis for patients at intermediate risk for febrile neutropenia.. Journal of Clinical Oncology. 39(28_suppl). 58–58. 1 indexed citations
5.
Patel, Anisha M., Shelby Corman, Stephen Chaplin, Karina Raimundo, & Robert F. Sidonio. (2019). Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. Journal of Medical Economics. 22(12). 1328–1337. 13 indexed citations
6.
7.
Chaplin, Stephen, et al.. (2015). What influences farmers' acceptance of agrienvironment schemes? An ex-post application of the 'Theory of Planned Behaviour'. OpenAgrar. 65(1). 15–28. 13 indexed citations
8.
Taylor, Matthew & Stephen Chaplin. (2013). The Economic Assessment of an Environmental Intervention: Discrete Deployment of Copper for Infection Control in ICUs. Value in Health. 16(7). A353–A353. 1 indexed citations
9.
Craig, Joyce, Stephen Chaplin, & Michelle Jenks. (2013). Warfarin monitoring economic evaluation of point of care self-monitoring compared to clinic settings. Journal of Medical Economics. 17(3). 184–190. 10 indexed citations
10.
Taylor, Matthew & Stephen Chaplin. (2013). P368: The economic assessment of an environmental intervention: discrete deployment of copper for infection control in ICUs. Antimicrobial Resistance and Infection Control. 2(S1). 1 indexed citations
11.
Dyson, Lisa, et al.. (2012). Mapping breastfeeding services: a method to inform effective implementation and evaluation of evidence‐based policy in practice. Maternal and Child Nutrition. 10(2). 253–266. 5 indexed citations
12.
Taylor, Matthew R.G., et al.. (2009). An Economic Evaluation of Valsartan for Post-MI Patients in the UK Who Are Not Suitable for Treatment with ACE Inhibitors. Value in Health. 12(4). 459–465. 12 indexed citations
13.
Taylor, Matthew, et al.. (2008). An economic evaluation of sevelamer in patients new to dialysis. Current Medical Research and Opinion. 24(2). 601–608. 25 indexed citations
14.
Peel, S. & Stephen Chaplin. (2008). Biodiversity of plants and animals in grassland systems: approaches to conservation and restoration in England.. UKnowledge (University of Kentucky). 993–998. 1 indexed citations
15.
Young, John, et al.. (2005). A whole system study of intermediate care services for older people. Age and Ageing. 34(6). 577–583. 36 indexed citations
16.
Young, John, et al.. (2005). A prospective baseline study of frail older people before the introduction of an intermediate care service. Health & Social Care in the Community. 13(4). 307–312. 21 indexed citations
17.
Scuffham, Paul & Stephen Chaplin. (2005). A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention. Clinical Therapeutics. 27(9). 1467–1477. 15 indexed citations
18.
Scuffham, Paul & Stephen Chaplin. (2004). An Economic Evaluation of Fluvastatin used for the Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention in the UK. PharmacoEconomics. 22(8). 525–535. 22 indexed citations
19.
Campoli-Richards, Deborah M., et al.. (1989). Netilmicin. Drugs. 38(5). 703–756. 30 indexed citations
20.
Ferner, R E, et al.. (1989). DRUGS IN DONATED BLOOD. The Lancet. 334(8654). 93–94. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Beatriz Rodríguez-Sánchez Breakdown of academic impact, for papers by Kristina H. Lewis Breakdown of academic impact, for papers by Laurence Bérard Breakdown of academic impact, for papers by Sidy Mohamed Seck Breakdown of academic impact, for papers by Luke E. Barry Breakdown of academic impact, for papers by Ritu Rana Breakdown of academic impact, for papers by Georgina Mulcahy Breakdown of academic impact, for papers by Praween Agrawal Breakdown of academic impact, for papers by Xiaoguang Yang Breakdown of academic impact, for papers by Vikki O’Neill
Rankless by CCL
2026